secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001213900-25-107821
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin
--------------------------------------------------------------------------------

- Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).
- In uncontrolled asthma subset (ACQ-5≥1.5, n=25), all doses showed significant ACQ-5 improvement; placebo-adjusted reductions 1.0–1.4.
- Placebo crossover (n=42) at week 24: EASI-75 60%, vIGA-AD 0/1 33%, EASI-90 37%, Itch NRS response 50%.
- Data support 24 μg/kg q2w dose with 24-week induction period for Phase 3 studies.
- Top-line Phase 2b data in alopecia areata expected December 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025107821/0001213900-25-107821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025107821/ea0264736-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-107821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer